In Q4, Regeneron reported EPS at $12.07, up from $11.86 in the same quarter last year. This print beat analysts’ estimates by 7.8%. Over the next 12 months, Wall Street expects Regeneron’s ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Tuesday reported fourth-quarter earnings of $917.7 million. On a per-share basis, the Tarrytown ...

Regeneron reported Q4 2024 EPS of $12.07, beating consensus estimates by 71 cents. Revenues rose 10.3% YoY to $3.79 billion, beating $3.74 billion consensus analyst estimates. Non-GAAP net income ...

Regeneron Pharmaceuticals ... with estimated sales of $17 billion. From Q4 2024 results, Dupixent revenue increased by 15% year-on-year, and with these extensions, I can foresee positive growth ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... sourced from Insider Monkey’s Q4 2024 database. Please note that the data was collected on February 28th ...

Also Read: Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program However, otoferlin-related hearing loss is ultra-rare. It is caused by variants in ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 10.3% year on year to $3.79 billion. Its non-GAAP profit of $12.07 per ...